The global market for stents in the treatment coronary artery disease, while dominated by drug-eluting stents, continues to also be comprised of a diversity of stent technologies. The market is evolving steadily as manufacturers aggressively seek optimal anti-restenosis, characterized by the goal of low rates of repeat revascularization. As with many medical technologies, prices, availability [...]
Translation: Drug-eluting stents are to bare metal stents as bare metal stents were to percutaneous transluminal coronary angioplasty alone. In the September 1 post on the meta-analysis by researchers at Tuft Medical Center, we noted the overall findings in general terms of the value of drug-eluting stents compared to bare metal stents. It is worthwhile to [...]
In a extensive meta-analysis of data from 12 clinical trials over nine years and 4,902 patients, researchers at the Division of Clinical Decision Making, Informatics and Telemedicine at Tufts Medical Center distilled the common thread of findings comparing drug-eluting with bare metal stents. The conclusion, succinctly, is: "Coronary drug-eluting stents significantly reduced the rates of [...]
The global coronary stent market faces continued growth, development and competition from a wide range of technology types and competitors. The market is detailed in a new report from MedMarket Diligence. FOR IMMEDIATE RELEASE PRLog (Press Release) – Aug 31, 2009 – Since the advent of coronary stents, followed by the emergence of drug eluting [...]
In spite of arguments contesting whether bare metal or drug-eluting stents perform better, drug-eluting stents are here to stay and are still used in the majority of stent implantations. In fact, a plethora of studies have shown that DES can improve mortality rates and reduce the need for target vessel revascularization (TVR) compared with BMS. [...]
Stent manufacturer, Xtent, Inc., announced on Monday, August 3, that its shareholders had approved the plan to dissolve the company and liquidate. With the dissolution originally announced in May, the company appeared poised for a comeback when its Custom NX stent received conditional IDE approval from the FDA in June. The hope was that the approval [...]
The market for coronary stents is, in many ways, still emerging. While coronary stents have been on the commercial market in one form or another for several years, the technologies and materials used to create the devices are improving every day. In addition, innovative technology is bringing new classes of devices (e.g., fully degradable stents) [...]
While coronary stents have been classed into the orginal bare metal stents, the now dominant drug-eluting stents and the soon-to-emerge bioabsorbable stents, a range of other novel stent technologys are in development by companies seeking to established a clinical and competitive advantage in the treatment of coronary artery disease. Below are specific stent technologies under [...]
Broken down by geographic region, the market for drug-eluting stents (DES) is growing at 9.0% in the United States, at 3.1% in Europe, at 10% in Asia/Pacific and 3.1% in ROW countries. Compounded annually from 2008 to 2017, the market for DES is growing 4.3% worldwide, 4.8% in the United States, 3.3% in Europe, 4.9% [...]
Below is a brief excerpt from "Absorbable Stents" from the MedMarket Diligence report #C245, "Worldwide Drug-Eluting, Bare and Other Coronary Stents, 2008-2017." The limitations of available metallic DES have created new interest in fully absorbable, fully biodegradable stents. The leading efforts in this area are sponsored by Abbott, Biotronik and REVA Medical. Only a handful [...]
Contact:
